Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-I AND PHARMACOLOGY STUDY OF FLAVONE ACETIC-ACID ADMINISTERED 2 OR 3 TIMES WEEKLY WITHOUT ALKALINIZATION
Autore:
DEFORNI M; CHABOT GG; ARMAND JP; GOUYETTE A; KLINKALAK M; RECONDO G;
Indirizzi:
INST GUSTAVE ROUSSY,PHARMACOTOXICOL & PHARMACOGENET LAB,CNRS,URA 147,PAVILLON RECH F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,PHARMACOTOXICOL & PHARMACOGENET LAB,CNRS,URA 147 F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT MED VILLEJUIF FRANCE
Titolo Testata:
Cancer chemotherapy and pharmacology
fascicolo: 3, volume: 35, anno: 1995,
pagine: 219 - 224
SICI:
0344-5704(1995)35:3<219:PAPSOF>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADVANCED MALIGNANT-MELANOMA; KILLER CELL-ACTIVITY; MURINE RENAL-CANCER; ANTITUMOR-ACTIVITY; SOLID TUMORS; NSC-347512; MICE; INTERLEUKIN-2; INDUCTION; CARCINOMA;
Keywords:
FLAVONE ACETIC ACID; PHASE I TRIAL; PHARMACOKINETICS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
M. Deforni et al., "PHASE-I AND PHARMACOLOGY STUDY OF FLAVONE ACETIC-ACID ADMINISTERED 2 OR 3 TIMES WEEKLY WITHOUT ALKALINIZATION", Cancer chemotherapy and pharmacology, 35(3), 1995, pp. 219-224

Abstract

Flavone acetic acid (FAA, NSC 347512) is a synthetic flavonoid compound with a unique form of preclinical antitumor activity, but its mechanism of action is still not known. In an attempt to exploit the remarkable preclinical activity of this compound in such a way as to allow its use as a clinically useful agent, we performed a phase I and pharmacology study with frequent administration and no hyperhydration or alkalinization. Sixteen patients (9 men, 7 women) were given FAA as 6-h i.v. infusions 2 or 3 times a week (10 and 6 patients, respectively), at doses ranging from 2.5 to 8.1 g/m(2). A total of 130 doses were administered during this study. Sedation, arterial hypotension, vomiting and diarrhea were the predominant toxicities observed at the highest dose (8.1 g/m(2)). One patient developed severe but reversible multiple organ failure. No treatment-related deaths occurred. Pharmacokinetics was linear for the doses studied, with peak plasma levels ranging from39 to 449 mu g/ml and a mean terminal half-life of 3.1 h. No drug accumulation was observed with this frequent-administration schedule. No objective response was observed. Three FAA infusions per week at 8.1 g/m(2) could be recommended as an optimal and tolerable schedule.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 08:03:55